Xponance Inc. Boosts Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Xponance Inc. boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 20.2% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,577 shares of the company’s stock after buying an additional 265 shares during the quarter. Xponance Inc.’s holdings in Krystal Biotech were worth $290,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Scout Investments Inc. purchased a new position in shares of Krystal Biotech during the 1st quarter worth $8,976,000. Sei Investments Co. lifted its stake in shares of Krystal Biotech by 128.3% during the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after purchasing an additional 18,968 shares during the period. Vanguard Group Inc. lifted its stake in shares of Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after purchasing an additional 35,632 shares during the period. Janney Montgomery Scott LLC purchased a new position in shares of Krystal Biotech during the 1st quarter worth $3,175,000. Finally, Braidwell LP lifted its stake in shares of Krystal Biotech by 153.2% during the 4th quarter. Braidwell LP now owns 196,200 shares of the company’s stock worth $24,341,000 after purchasing an additional 118,703 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 0.3 %

Shares of NASDAQ KRYS opened at $181.47 on Wednesday. Krystal Biotech, Inc. has a 12-month low of $93.95 and a 12-month high of $219.34. The company has a market cap of $5.18 billion, a P/E ratio of 97.04 and a beta of 0.82. The stock has a fifty day moving average price of $191.97 and a 200 day moving average price of $179.71.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same period in the prior year, the firm earned ($1.25) EPS. The firm’s quarterly revenue was up 70283900.0% compared to the same quarter last year. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on KRYS shares. William Blair raised Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Evercore ISI upped their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Citigroup restated a “neutral” rating and set a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Stifel Nicolaus upped their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $196.75.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).